Neuroendocrine tumors of the gastroenteropancreatic tract remain a difficult array of neoplasia to treat. Treatment ofadvanced and metastatic gastroenteropancreatic neuroendocrine tumors has traditionally been difficult with few systemictreatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreaticneuroendocrine tumor. The approval of these agents led to an enhanced interest in exploring novel agents. This can beevidenced by the fact that this is the first year that ASCO assembled related abstracts under a separate title ofneuroendocrine tumor. The annual American Society of Clinical Oncology (ASCO) conference in 2013 presented fourabstracts (#4030, #4031, #4032, #4136) that shed light on new therapeutic options that help target the unique pathwaysinvolved in these neuroendocrine malignancies.
Muhammad Wasif Saif, Simon Khagi
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : September 22, 2019